NCT01214291View on ClinicalTrials.gov

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Risk of Bone Fracture Occurrences
Interventions
DRUG

Toremifene

Toremifene 80mg daily

Trial Locations (1)

98108

VA Puget Sound, Seattle

Sponsors

Lead Sponsor

GTx

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

GTx

INDUSTRY

NCT01214291 - Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer | Biotech Hunter | Biotech Hunter